{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:33:49Z","timestamp":1793212429174,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Artificial intelligence (AI) is increasingly being used to support clinical research, but its value in vaccine clinical trials requires careful evidence-based assessment. Vaccine trials pose distinctive challenges, including high safety expectations in healthy participants, evolving pathogen exposure and baseline immunity, incomplete correlates of protection, applicability of findings to intended-use populations, and intense public scrutiny. We conducted a structured, vaccine-focused narrative review of AI applications across the vaccine-trial lifecycle, supplemented by targeted clinical trial and vaccine pharmacovigilance studies with directly transferable methods. In the combined evidence base, evidence is strongest for operational uses, particularly recruitment, eligibility screening, trial matching, and risk-based monitoring. Applications to immune-response interpretation, correlates of protection, and vaccine safety surveillance are promising but remain less prospectively validated. Responsible adoption should be guided by intended tool use, strength of evidence, data governance, regulatory expectations, and preservation of human scientific and safety judgment.<\/jats:p>","DOI":"10.1093\/cid\/ciag445","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:47:33Z","timestamp":1784116053000},"page":"618-624","source":"Crossref","is-referenced-by-count":0,"title":["Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails"],"prefix":"10.1093","volume":"83","author":[{"given":"Jad","family":"Idriss","sequence":"first","affiliation":[{"name":"Hope Clinic, Infectious Diseases Division, Department of Medicine, School of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3755-7771","authenticated-orcid":false,"given":"Suha","family":"Kalash","sequence":"additional","affiliation":[{"name":"Hope Clinic, Infectious Diseases Division, Department of Medicine, School of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Abu Faraj","sequence":"additional","affiliation":[{"name":"Hope Clinic, Infectious Diseases Division, Department of Medicine, School of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1489-513X","authenticated-orcid":false,"given":"Lauren","family":"Nolan","sequence":"additional","affiliation":[{"name":"Emory Children's Center Vaccine Research Clinic, Infectious Diseases Division, Department of Pediatrics, School of Medicine, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Bechnak","sequence":"additional","affiliation":[{"name":"Hope Clinic, Infectious Diseases Division, Department of Medicine, School of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-7919","authenticated-orcid":false,"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[{"name":"Hope Clinic, Infectious Diseases Division, Department of Medicine, School of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2026102813500688900_ciag445-B1","doi-asserted-by":"crossref","first-page":"eadu3791","DOI":"10.1126\/scitranslmed.adu3791","article-title":"Vaccinology in the artificial intelligence era","volume":"17","author":"Gasperini","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026102813500688900_ciag445-B2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12553-023-00738-2","article-title":"Artificial intelligence applied to clinical trials: opportunities and challenges","volume":"13","author":"Askin","year":"2023","journal-title":"Health Technol (Berl)"},{"key":"2026102813500688900_ciag445-B3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"2026102813500688900_ciag445-B4","doi-asserted-by":"crossref","first-page":"m3164","DOI":"10.1136\/bmj.m3164","article-title":"Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension","volume":"370","author":"Liu","year":"2020","journal-title":"BMJ"},{"key":"2026102813500688900_ciag445-B5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/healthcare12060644","article-title":"Reducing sample size while improving equity in vaccine clinical trials: a machine learning-based recruitment methodology with application to improving trials of hepatitis C virus vaccines in people who inject drugs","volume":"12","author":"Chiu","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"2026102813500688900_ciag445-B6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7774\/cevr.2025.14.e21","article-title":"Multilevel systems biology analysis identifies key immune response profiles and potential correlates of protection for M72\/AS01E vaccine against tuberculosis","volume":"14","author":"Taofeek","year":"2025","journal-title":"Clin Exp Vaccine Res"},{"key":"2026102813500688900_ciag445-B7","doi-asserted-by":"crossref","first-page":"asae061","DOI":"10.1093\/biomet\/asae061","article-title":"Assessing variable importance in survival analysis using machine learning","volume":"112","author":"Wolock","year":"2024","journal-title":"Biometrika"},{"key":"2026102813500688900_ciag445-B8","doi-asserted-by":"crossref","first-page":"e1012188","DOI":"10.1371\/journal.pcbi.1012188","article-title":"Predicting the infecting dengue serotype from antibody titre data using machine learning","volume":"20","author":"Cracknell Daniels","year":"2024","journal-title":"PLoS Comput Biol"},{"key":"2026102813500688900_ciag445-B9","doi-asserted-by":"crossref","first-page":"e1012131","DOI":"10.1371\/journal.pcbi.1012131","article-title":"Machine learning prediction of malaria vaccine efficacy based on antibody profiles","volume":"20","author":"Wistuba-Hamprecht","year":"2024","journal-title":"PLoS Comput Biol"},{"key":"2026102813500688900_ciag445-B10","doi-asserted-by":"crossref","first-page":"e1013705","DOI":"10.1371\/journal.pcbi.1013705","article-title":"Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning","volume":"21","author":"Xu","year":"2025","journal-title":"PLoS Comput Biol"},{"key":"2026102813500688900_ciag445-B11","doi-asserted-by":"crossref","first-page":"1259197","DOI":"10.3389\/fimmu.2023.1259197","article-title":"Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts","volume":"14","author":"Gonzalez Dias Carvalho","year":"2023","journal-title":"Front Immunol"},{"key":"2026102813500688900_ciag445-B12","doi-asserted-by":"crossref","first-page":"100886","DOI":"10.1016\/j.landig.2025.100886","article-title":"Development of machine learning prediction models for systemic inflammatory response following controlled exposure to a live attenuated influenza vaccine in healthy adults using multimodal wearable biosensors in Canada: a single-centre, prospective controlled trial","volume":"7","author":"Hadid","year":"2025","journal-title":"Lancet Digit Health"},{"key":"2026102813500688900_ciag445-B13","volume-title":"Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle","author":"European Medicines Agency","year":"2024"},{"key":"2026102813500688900_ciag445-B14"},{"key":"2026102813500688900_ciag445-B15","doi-asserted-by":"crossref","first-page":"e0300109","DOI":"10.1371\/journal.pone.0300109","article-title":"Enhancing site selection strategies in clinical trial recruitment using real-world data modeling","volume":"19","author":"Hulstaert","year":"2024","journal-title":"PLoS One"},{"key":"2026102813500688900_ciag445-B16","doi-asserted-by":"crossref","first-page":"e0263193","DOI":"10.1371\/journal.pone.0263193","article-title":"Prediction of clinical trial enrollment rates","volume":"17","author":"Bieganek","year":"2022","journal-title":"PLoS One"},{"key":"2026102813500688900_ciag445-B17","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1038\/s41598-025-88400-x","article-title":"Predicting accrual success for better clinical trial resource allocation","volume":"15","author":"Ma","year":"2025","journal-title":"Sci Rep"},{"key":"2026102813500688900_ciag445-B18","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1038\/s41467-024-53081-z","article-title":"Matching patients to clinical trials with large language models","volume":"15","author":"Jin","year":"2024","journal-title":"Nat Commun"},{"key":"2026102813500688900_ciag445-B19","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/jamia\/ocae073","article-title":"Distilling large language models for matching patients to clinical trials","volume":"31","author":"Nievas","year":"2024","journal-title":"J Am Med Inform Assoc"},{"key":"2026102813500688900_ciag445-B20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2024.28047","article-title":"Manual vs AI-assisted prescreening for trial eligibility using large language models\u2014a randomized clinical trial","volume":"333","author":"Unlu","year":"2025","journal-title":"JAMA"},{"key":"2026102813500688900_ciag445-B21","doi-asserted-by":"crossref","first-page":"e252013","DOI":"10.1001\/jamanetworkopen.2025.2013","article-title":"Clinical trial notifications triggered by artificial intelligence\u2013detected cancer progression: a randomized trial","volume":"8","author":"Mazor","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026102813500688900_ciag445-B22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/17407745241297947","article-title":"Detecting irregularities in randomized controlled trials using machine learning","volume":"22","author":"Nelson","year":"2025","journal-title":"Clin Trials"},{"key":"2026102813500688900_ciag445-B23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s43441-025-00754-6","article-title":"Optimizing quality tolerance limits monitoring in clinical trials through machine learning methods","volume":"59","author":"Yan","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"2026102813500688900_ciag445-B24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41541-024-00872-6","article-title":"Realising the potential of correlates of protection for vaccine development, licensure and use: short summary","volume":"9","author":"King","year":"2024","journal-title":"npj Vaccines"},{"key":"2026102813500688900_ciag445-B25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40264-023-01381-6","article-title":"Optimizing signal management in a vaccine adverse event reporting system: a proof-of-concept with COVID-19 vaccines using signs, symptoms, and natural language processing","volume":"47","author":"Dong","year":"2024","journal-title":"Drug Saf"},{"key":"2026102813500688900_ciag445-B26","author":"CDC"},{"key":"2026102813500688900_ciag445-B27","doi-asserted-by":"crossref","first-page":"e0300919","DOI":"10.1371\/journal.pone.0300919","article-title":"AE-GPT: using large language models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events","volume":"19","author":"Li","year":"2024","journal-title":"PLoS One"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag445\/69150122\/ciag445.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/4\/618\/69150122\/ciag445.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/4\/618\/69150122\/ciag445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:50:16Z","timestamp":1793209816000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/4\/618\/8736409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,17]]},"published-print":{"date-parts":[[2026,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag445","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,7,17]]}}}